Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Change in Accured Expenses (2016 - 2026)

Insight Molecular Diagnostics' Change in Accured Expenses history spans 6 years, with the latest figure at $3.6 million for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 404.97% to $3.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.6 million, a 173.63% increase, with the full-year FY2025 number at $2.6 million, up 173.63% from a year prior.
  • Change in Accured Expenses hit $3.6 million in Q4 2025 for Insight Molecular Diagnostics, up from $1.2 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for IMDX hit a ceiling of $3.6 million in Q4 2025 and a floor of -$3.1 million in Q2 2025.
  • Historically, Change in Accured Expenses has averaged -$109750.0 across 5 years, with a median of $154500.0 in 2022.
  • Biggest five-year swings in Change in Accured Expenses: tumbled 12576.19% in 2023 and later surged 415.08% in 2024.
  • Tracing IMDX's Change in Accured Expenses over 5 years: stood at $244000.0 in 2021, then plummeted by 151.23% to -$125000.0 in 2022, then plummeted by 351.2% to -$564000.0 in 2023, then skyrocketed by 224.82% to $704000.0 in 2024, then soared by 404.97% to $3.6 million in 2025.
  • Business Quant data shows Change in Accured Expenses for IMDX at $3.6 million in Q4 2025, $1.2 million in Q3 2025, and -$3.1 million in Q2 2025.